At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
Tarlatamabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer
In Brief
A Phase 1 clinical trial evaluating Tarlatamab for Neuroendocrine Prostate Cancer. Completed, enrolled 41 participants across 21 sites in 9 countries.
Detailed Summary
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Prostate Cancer
CountriesAustralia, Austria, Belgium, France, Japan, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJun 2021
Primary CompletionJul 2024
TodayJul 2026
First PostedJan 11, 2021
Enrollment StartJun 10, 2021
Primary CompletionJul 22, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 5.5 years ago
Interventions
Tarlatamabdrug
Tarlatamab will be administered as an intravenous (IV) infusion.